

BSE Limited
P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation regarding completion of term of Independent Director

Ref.: Regulation 30 and 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

With reference to the captioned subject, we wish to inform you that Mr. Bharat Anand (DIN: 02806475) has completed his second term as an Independent Director of the Company and consequently, has ceased to be an Independent Director of the Company with effect from August 30, 2026.

Accordingly, Mr. Bharat Anand has also ceased to be a member of the following Board Committees:

1. Audit Committee;
2. Nomination and Remuneration Committee;
3. Risk Management Committee; and
4. Corporate Social Responsibility Committee.

The Board of Directors and the Management of the Company place on record their sincere appreciation for the valuable contribution, guidance and support provided by Mr. Bharat Anand during his association with the Company as an Independent Director.

The details as required under the Listing Regulations, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (“SEBI Master Circular”), are enclosed herewith as **Annexure-I**.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary &
Compliance Officer

Encl.: A/a

Annexure-I

Details as required under Regulation 30 of Listing Regulations read with SEBI Master Circular:

S. No.	Particulars	Details
1	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Cessation due to completion of his second term.
2	Date of appointment / re-appointment / cessation (as applicable) & term of appointment/re-appointment	August 30, 2026
3	Brief profile (in case of appointment)	Not Applicable
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com